Kiromic BioPharma News

Kiromic BioPharma | 10-Q: Quarterly report

Futu NewsMay 10 22:39 · Announcements

Kiromic Biopharma Outlines Vision in Stakeholder Meetings

TipRanksApr 20 04:43

Kiromic BioPharma Files to Withdraw Registration Statement

Seeking AlphaApr 11 05:19

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial

PDF Version Favorable Safety and Tolerability also Observed HOUSTON--(BUSINESS WIRE)--Mar. 19, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports early efficacy res

Kiromic BioPharmaMar 19 12:00

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Yahoo FinanceMar 8 21:35

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Yahoo FinanceMar 5 21:35

Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

PDF Version Third Patient Enrolled in Deltacel-01 Completes Treatment HOUSTON--(BUSINESS WIRE)--Mar. 1, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") announces that Vi

Kiromic BioPharmaMar 1 13:00

Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th

PDF Version Live and Archived Fireside Chat Available at VirtualInvestorConferences.com HOUSTON--(BUSINESS WIRE)--Feb. 28, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company"

Kiromic BioPharmaFeb 28 13:00

Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth

TipRanksFeb 15 05:45

Results From First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

PDF Version Second Patient Completed Treatment and Third Patient Dosed in Phase 1 Study Evaluating Deltacel for the Treatment of Non-Small Cell Lung Cancer HOUSTON--(BUSINESS WIRE)--Feb. 14, 2024

Kiromic BioPharmaFeb 14 13:00

Kiromic BioPharma Reports Favorable Early Efficacy Results From First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

PDF Version Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated HOUSTON--(BUSINESS WIRE)--Jan. 29, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or th

Kiromic BioPharmaJan 29 13:00

Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data From First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

PDF Version Company Executives Available to Meet with Investment Professionals January 8-10 in San Francisco HOUSTON--(BUSINESS WIRE)--Jan. 5, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kirom

Kiromic BioPharmaJan 5 13:00

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel for the Treatment of Non-Small Cell Lung Cancer

PDF Version Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 HOUSTON--(BUSINESS WIRE)--Dec. 14, 2023-- Kiromi

Kiromic BioPharmaDec 14, 2023 13:00

Kiromic BioPharma Announces Deltacel Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center

PDF Version Company is Activating Additional Clinical Trial Sites Across the U.S. HOUSTON--(BUSINESS WIRE)--Nov. 9, 2023--Kiromic BioPharma, Inc. (OTC PINK: KRBP) ("Kiromic" or the "Company"), a

Kiromic BioPharmaNov 9, 2023 13:00

Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

PDF Version Beverly Hills Cancer Center is the first of up to four prestigious clinical sites expected to evaluate Deltacel (KB-GDT-01) in patients with non-small cell lung cancer HOUSTON--(BUSIN

Kiromic BioPharmaOct 23, 2023 12:00

GRI Bio, HealthStream, Kiromic BioPharma Among Healthcare Movers

Seeking AlphaSep 14, 2023 22:00

Kiromic Biopharma Shares Suspended From Trading on Nasdaq

Kiromic BioPharma (KRBP) said Wednesday that it has been notified that its common shares were suspended from trading on the Nasdaq Capital Market, effective Sept. 14, due to failure to demonstrate com

MT NewswiresSep 14, 2023 18:36

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersInfinity Pharmaceuticals (NASDAQ:INFI) shares increased by 23.7% to $0.04 during Wednesday's after-market session. Trading volume for this security closed at 3.2 million, accounting for 94.2% o

BenzingaSep 14, 2023 05:31

Kiromic BioPharma to List on OTC Pink Sheets After Nasdaq Trading Suspension

Seeking AlphaSep 14, 2023 04:50

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

PDF Version KRBP Suspended from Trading on Nasdaq HOUSTON--(BUSINESS WIRE)--Sep. 13, 2023-- Kiromic BioPharma (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated bioth

Kiromic BioPharmaSep 13, 2023 12:00